Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. (Nasdaq: BMEA) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity, and its news flow reflects this focus on metabolic disease. Company updates frequently center on the progress of its two main investigational programs: icovamenib, an oral covalent menin inhibitor for insulin-deficient diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist candidate for obesity and related metabolic disorders.
News items for BMEA commonly include clinical trial milestones, such as Phase II data readouts for icovamenib in type 2 diabetes, long-term follow-up results, and the initiation or advancement of studies like COVALENT-111, COVALENT-121, COVALENT-211, COVALENT-212, and GLP-131. Biomea Fusion also reports on preclinical findings, including combination data for icovamenib with GLP-1–based therapies and weight-loss and pharmacology data for BMF-650 in animal models.
Investors following BMEA news will also see corporate and financial announcements, such as quarterly financial results, cost-management updates, and underwritten offerings of common stock and warrants. The company regularly issues press releases about its participation in scientific and investor conferences, including oral presentations at diabetes and obesity meetings and fireside chats at healthcare investment conferences.
This news page aggregates these disclosures so readers can track Biomea Fusion’s clinical progress, scientific presentations, financing activities, and other material events. For those monitoring the development of investigational therapies in diabetes and obesity, the BMEA news feed offers a centralized view of the company’s reported milestones and public communications over time.
Biomea Fusion (BMEA) announced positive topline results from its Phase II COVALENT-111 study evaluating icovamenib in type 2 diabetes patients. The study met its primary endpoint, showing statistically significant HbA1c reductions across all major categories. The most significant results were observed in insulin-deficient patients, with a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 in the severe insulin-deficient diabetes (SIDD) group.
The study enrolled 225 patients, with 168 completing the per-protocol analysis. The optimal dosing was identified as 100mg once daily for 12 weeks, showing a mean HbA1c reduction of 0.5%. Notably, the drug demonstrated efficacy in patients who failed GLP-1 based therapy, achieving an HbA1c reduction of 0.84%. The treatment was well-tolerated with no serious adverse events or discontinuations due to adverse events.
Biomea Fusion (BMEA) has announced a conference call and webcast scheduled for Tuesday, December 17, 2024, at 8:00 am EST to present topline results from COVALENT-111, their Phase II trial of icovamenib in patients with type 2 diabetes. The company, which focuses on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, will make the webcast available to registered attendees through their investor relations website, with a replay available afterward.
Biomea Fusion (NASDAQ: BMEA) presented significant preclinical findings for icovamenib, their investigational covalent menin inhibitor, at the 22nd WCIRDC. The research demonstrated that icovamenib enhanced beta cell function and improved responsiveness to GLP-1-based therapies in human islets. Key findings showed increased expression of GLP-1 receptors and intracellular insulin, with synergistic effects when combined with therapies like semaglutide and tirzepatide.
The data suggests that icovamenib's ability to increase beta cell mass could potentially allow for lower doses of GLP-1-based therapies while maintaining glycemic targets, potentially reducing side effects. Clinical case studies indicated that short-term icovamenib treatment was well-tolerated with no significant adverse events or hypoglycemia reported.
Biomea Fusion (BMEA) announced preliminary data from its Phase I COVALENT-103 study of BMF-500, a covalent FLT3 inhibitor for relapsed or refractory acute leukemia. The study enrolled 20 patients, including 13 with confirmed FLT3-mutations, who had previously failed gilteritinib treatment.
Key findings include: no dose-limiting toxicities across all dose levels, favorable safety profile, and demonstrated FLT3 inhibition with bone marrow penetration. Clinical activity was observed with one complete response with incomplete hematologic recovery (CRi) at 100mg twice daily dosing, and bone marrow blast reductions in 5 of 6 evaluable FLT3 mutated patients.
The highlighted case study showed a CRi in a 61-year-old patient with R/R AML who had failed four prior treatment regimens.
Biomea Fusion (NASDAQ: BMEA) has announced a conference call and webcast scheduled for December 9, 2024, at 4:30 pm EST. The presentation will reveal initial clinical data from the Phase I COVALENT-103 study of BMF-500, their investigational covalent FLT3 inhibitor, in patients with relapsed or refractory acute leukemia.
BMF-500 was developed using Biomea's proprietary FUSION™ System. The webcast will be accessible to registered attendees through the company's investor relations website, with a replay available after the event.
Biomea Fusion announced that its compensation committee granted stock options to one new employee on December 2, 2024. The grant includes options to purchase 30,000 shares of common stock, which will vest quarterly over four years at a rate of 1/16. The grant was made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, and serves as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Biomea Fusion presented new analysis from COVALENT-111 trial at ATTD-ASIA 2024, showing promising results for icovamenib in Type 2 Diabetes (T2D) treatment. The study revealed that insulin-deficient patients (approximately 50% of the population) showed a greater mean HbA1c reduction (-1.23% vs -0.48%) compared to insulin-resistant patients at Week 26, following 4 weeks of dosing.
Notable case studies included a 29-year-old patient achieving a 2.5% HbA1c reduction and a 45-year-old patient showing a 1.1% reduction, both with significant improvements in HOMA-B and C-peptide levels. The company expects topline results from the Phase IIb expansion portion, involving over 200 T2D patients, in December.
Biomea Fusion announced that its compensation committee granted stock options to one new employee on November 1, 2024. The grant includes options to purchase 6,500 shares of common stock, which will vest quarterly over four years at a rate of 1/16. The award was made under Biomea's 2023 Inducement Equity Plan and granted as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Biomea Fusion presented preclinical data showing that icovamenib (BMF-219) enhanced the effectiveness of GLP-1-based therapies in diabetes treatment. Ex vivo human islet experiments demonstrated increased insulin secretion when icovamenib was combined with tirzepatide or semaglutide. The company plans to initiate a Phase II study (COVALENT-211) combining icovamenib with GLP-1-based therapy in 2025.
Additionally, Biomea introduced BMF-650, a next-generation oral small-molecule GLP-1 receptor agonist candidate, which showed promising preclinical results including improved glucose-stimulated insulin secretion, better glucose control, and appetite suppression in cynomolgus monkeys.
Biomea Fusion reported Q3 2024 financial results and corporate updates. The FDA lifted clinical holds on COVALENT-111 (Type 2 Diabetes) and COVALENT-112 (Type 1 Diabetes) trials. The company expects topline data from both studies in December 2024. Cash position stood at $88.3 million as of September 30, 2024. Q3 net loss was $32.8 million, with R&D expenses at $27.2 million and G&A expenses at $6.8 million. The company plans to announce its third clinical candidate, BMF-650, an oral GLP-1 receptor agonist for diabetes and obesity treatment.